Accurate prediction of Aβ-positivity using a range of cheap, non-invasive biomarkers.


  • Application of non-invasive biomarker data to the reported algorithms can accurately predict the risk of Aβ-positivity.

Why this matters

  • Non-invasive, relatively cheap biomarkers to indicate the level of risk of being Aβ-positive would greatly reduce the reliance on costly alternatives, and hasten the identification of patients with prodromal Alzheimer’s disease (AD) for inclusion in trials, and ultimately treatment.